Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.69 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.69 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.69 |
| ▸ | SAT1 | P21673 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7766302 | 1.00 | GNAI3 (0.69) | GNAI3GNAO1GNAI1SAT1TSHR | |
| SCHEMBL17718455 | 0.98 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1TSHR | |
| SCHEMBL7767956 | 0.98 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1TSHR | |
| SCHEMBL19414059 | 0.98 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1TSHR | |
| SCHEMBL11541786 | 0.98 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1TSHR | |
| SCHEMBL1678448 | 0.98 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1TSHR | |
| SCHEMBL11539085 | 0.98 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1TSHR | |
| SCHEMBL1933069 | 0.98 | GNAI3 (0.72) | GNAI3GNAO1GNAI1SAT1TSHR | |
| SCHEMBL23468518 | 0.96 | GNAI3 (0.70) | GNAI3GNAO1GNAI1SAT1TSHR | |
| SCHEMBL23468533 | 0.96 | GNAI3 (0.70) | GNAI3GNAO1GNAI1SAT1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000784-A1 | Autophagy Inhibitors | VAN ANDEL RESEARCH INSTITUTE | 2017-01-05 | — | — | US | disclosed |
| US-20160137607-A1 | Autophagy Inhibitors | VAN ANDEL RESEARCH INSTITUTE | 2016-05-19 | — | — | US | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9221760-B2 | Autophagy inhibitors | VAN ANDEL RESEARCH INSTITUTE (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015085229-A1 | AUTOPHAGY INHIBITORS | VAN ANDEL RESEARCH INSTITUTE (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20140148451-A1 | Autophagy Inhibitors | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2014-05-29 | — | — | US | disclosed |
| EP-2262808-B1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| CN-1068583-C | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL MYERS SQUIBB CO (US) | 2001-07-18 | — | — | CN | disclosed |
| EP-0747346-B1 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL MYERS SQUIBB CO (US) | 2000-02-16 | — | — | EP | disclosed |
| EP-0747346-B1 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL MYERS SQUIBB CO (US) | 2000-02-16 | — | — | EP | disclosed |
| US-5889031-A | CONTROLLING CIRCADIAN RHYTHMS | BRISTOL-MYERS SQUIBB COMPNAY (US) | 1999-03-30 | — | — | US | disclosed |
| US-5753709-A | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-19 | — | — | US | disclosed |
| US-5753709-A | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0747346-A3 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-11-05 | — | — | EP | disclosed |
| CN-1143628-A | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL MYERS SQUIBB CO (US) | 1997-02-26 | — | — | CN | disclosed |
| EP-0747346-A2 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0747346-A2 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000784-A1 | Autophagy Inhibitors | BRAF, HRAS, NRAS | GNAI3 751/4885GNAO1 1908/4885GNAI1 669/4885 |
| US-20140148451-A1 | Autophagy Inhibitors | BECN1, ATG7, SQSTM1 | GNAI3 556/4885GNAO1 2761/4885GNAI1 815/4885 |
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | GNAI3 316/4885GNAO1 589/4885GNAI1 248/4885 |
| US-20160137607-A1 | Autophagy Inhibitors | BECN1, ATG7, SQSTM1 | GNAI3 556/4885GNAO1 2761/4885GNAI1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.